
Chronic Spontaneous Urticaria

Podcasts
Continuing Medical Education
All News
Advertisement

A WhatsApp-based pilot study revealed high patient knowledge and significant challenges in managing CSU among Spanish speakers.

Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.
Advertisement
Advertisement
Trending on Dermatology Times
1
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Quality of Life in CSU Shaped by More Than Skin Symptoms
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5



































